Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4

Hamad Al Ashgar, Ahmed Helmy, Mohamed Q. Khan, Khalid Al Kahtani, Mohammed Al Quaiz, Mohammed Rezeig, Ingvar Kagevi, Abdullah Alshehri, Abdullah Al Kalbani, Khalid Al Swat, Salim Dahab, Naser Elkum, Mohammed Al Fadda

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background and objectives: Knowledge of the predictors of sustained viral response (SVR) to pegylated interferon (PEG-INF) alfa-2a and ribavirin (RBV) therapy in patients with hepatitis C genotype-4 (HCV-4) is crucial for selecting patients who would benefit most from therapy. We assessed the predictors of SVR to this combination therapy in Saudi patients with chronic HCV-4 infection. Patients and methods: This retrospective study included 148 patients with HCV-4 infection who underwent clinical, biochemical and virological assessments before treatment and at 12, 24, 48 and 72 weeks post-treatment. Results: Of the 148 patients, 90 (60.8%) were males. Mean (SD) for age was 48. 5 (12.7) years and BMI was 27.9 (7.5) kg/m2. Seventy-nine of 148 (60.1%) patients were treatment naïve and 110 (74.3%) underwent pre-treatment liver biopsy. Eighteen (12.2%) patients did not complete therapy because of side effects or they were lost to follow up. Early virological response was achieved in 84 of 91 (92.3%) patients. In the 130 (87.8%) patients who completed therapy, 34 (26.2%) were non-responders and 96 (63.8%) achieved end-of-treatment virological response (ETVR). SVR and virological relapse (24 weeks after ETVR) occurred in 66/130 (50.7%) and 30/130 (31.2%) patients, respectively. Compared to relapsers, sustained responders were significantly younger (P=.005), non-diabetic (P=.005), had higher serum albumin (P=.028), lower alpha-fetoprotein level (P=.026), lower aspartate aminotransferase (AST) (P=.04) levels, and were treatment-naïve (P=.008). In a multivariate regression analysis, the independent predictors of SVR were younger age (P=.016), lower serum AST (P=.012), and being treatment naïve (P=.021). Conclusion: Approximately half of HCV-4 patients who complete the course of combination therapy achieve an SVR, especially if they are young, treatment naïve and have lower AST levels.

Original languageEnglish
Pages (from-to)4-14
Number of pages11
JournalAnnals of Saudi Medicine
Volume29
Issue number1
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Ribavirin
Hepacivirus
Genotype
Therapeutics
Aspartate Aminotransferases
peginterferon alfa-2a
Lost to Follow-Up
alpha-Fetoproteins
Hepatitis C
Infection
Serum Albumin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. / Al Ashgar, Hamad; Helmy, Ahmed; Khan, Mohamed Q.; Al Kahtani, Khalid; Al Quaiz, Mohammed; Rezeig, Mohammed; Kagevi, Ingvar; Alshehri, Abdullah; Al Kalbani, Abdullah; Al Swat, Khalid; Dahab, Salim; Elkum, Naser; Al Fadda, Mohammed.

In: Annals of Saudi Medicine, Vol. 29, No. 1, 2009, p. 4-14.

Research output: Contribution to journalArticle

Al Ashgar, H, Helmy, A, Khan, MQ, Al Kahtani, K, Al Quaiz, M, Rezeig, M, Kagevi, I, Alshehri, A, Al Kalbani, A, Al Swat, K, Dahab, S, Elkum, N & Al Fadda, M 2009, 'Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4', Annals of Saudi Medicine, vol. 29, no. 1, pp. 4-14.
Al Ashgar, Hamad ; Helmy, Ahmed ; Khan, Mohamed Q. ; Al Kahtani, Khalid ; Al Quaiz, Mohammed ; Rezeig, Mohammed ; Kagevi, Ingvar ; Alshehri, Abdullah ; Al Kalbani, Abdullah ; Al Swat, Khalid ; Dahab, Salim ; Elkum, Naser ; Al Fadda, Mohammed. / Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. In: Annals of Saudi Medicine. 2009 ; Vol. 29, No. 1. pp. 4-14.
@article{70d41155a74545a3b69a12077e6187ed,
title = "Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4",
abstract = "Background and objectives: Knowledge of the predictors of sustained viral response (SVR) to pegylated interferon (PEG-INF) alfa-2a and ribavirin (RBV) therapy in patients with hepatitis C genotype-4 (HCV-4) is crucial for selecting patients who would benefit most from therapy. We assessed the predictors of SVR to this combination therapy in Saudi patients with chronic HCV-4 infection. Patients and methods: This retrospective study included 148 patients with HCV-4 infection who underwent clinical, biochemical and virological assessments before treatment and at 12, 24, 48 and 72 weeks post-treatment. Results: Of the 148 patients, 90 (60.8{\%}) were males. Mean (SD) for age was 48. 5 (12.7) years and BMI was 27.9 (7.5) kg/m2. Seventy-nine of 148 (60.1{\%}) patients were treatment na{\"i}ve and 110 (74.3{\%}) underwent pre-treatment liver biopsy. Eighteen (12.2{\%}) patients did not complete therapy because of side effects or they were lost to follow up. Early virological response was achieved in 84 of 91 (92.3{\%}) patients. In the 130 (87.8{\%}) patients who completed therapy, 34 (26.2{\%}) were non-responders and 96 (63.8{\%}) achieved end-of-treatment virological response (ETVR). SVR and virological relapse (24 weeks after ETVR) occurred in 66/130 (50.7{\%}) and 30/130 (31.2{\%}) patients, respectively. Compared to relapsers, sustained responders were significantly younger (P=.005), non-diabetic (P=.005), had higher serum albumin (P=.028), lower alpha-fetoprotein level (P=.026), lower aspartate aminotransferase (AST) (P=.04) levels, and were treatment-na{\"i}ve (P=.008). In a multivariate regression analysis, the independent predictors of SVR were younger age (P=.016), lower serum AST (P=.012), and being treatment na{\"i}ve (P=.021). Conclusion: Approximately half of HCV-4 patients who complete the course of combination therapy achieve an SVR, especially if they are young, treatment na{\"i}ve and have lower AST levels.",
author = "{Al Ashgar}, Hamad and Ahmed Helmy and Khan, {Mohamed Q.} and {Al Kahtani}, Khalid and {Al Quaiz}, Mohammed and Mohammed Rezeig and Ingvar Kagevi and Abdullah Alshehri and {Al Kalbani}, Abdullah and {Al Swat}, Khalid and Salim Dahab and Naser Elkum and {Al Fadda}, Mohammed",
year = "2009",
language = "English",
volume = "29",
pages = "4--14",
journal = "Annals of Saudi Medicine",
issn = "0256-4947",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

TY - JOUR

T1 - Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4

AU - Al Ashgar, Hamad

AU - Helmy, Ahmed

AU - Khan, Mohamed Q.

AU - Al Kahtani, Khalid

AU - Al Quaiz, Mohammed

AU - Rezeig, Mohammed

AU - Kagevi, Ingvar

AU - Alshehri, Abdullah

AU - Al Kalbani, Abdullah

AU - Al Swat, Khalid

AU - Dahab, Salim

AU - Elkum, Naser

AU - Al Fadda, Mohammed

PY - 2009

Y1 - 2009

N2 - Background and objectives: Knowledge of the predictors of sustained viral response (SVR) to pegylated interferon (PEG-INF) alfa-2a and ribavirin (RBV) therapy in patients with hepatitis C genotype-4 (HCV-4) is crucial for selecting patients who would benefit most from therapy. We assessed the predictors of SVR to this combination therapy in Saudi patients with chronic HCV-4 infection. Patients and methods: This retrospective study included 148 patients with HCV-4 infection who underwent clinical, biochemical and virological assessments before treatment and at 12, 24, 48 and 72 weeks post-treatment. Results: Of the 148 patients, 90 (60.8%) were males. Mean (SD) for age was 48. 5 (12.7) years and BMI was 27.9 (7.5) kg/m2. Seventy-nine of 148 (60.1%) patients were treatment naïve and 110 (74.3%) underwent pre-treatment liver biopsy. Eighteen (12.2%) patients did not complete therapy because of side effects or they were lost to follow up. Early virological response was achieved in 84 of 91 (92.3%) patients. In the 130 (87.8%) patients who completed therapy, 34 (26.2%) were non-responders and 96 (63.8%) achieved end-of-treatment virological response (ETVR). SVR and virological relapse (24 weeks after ETVR) occurred in 66/130 (50.7%) and 30/130 (31.2%) patients, respectively. Compared to relapsers, sustained responders were significantly younger (P=.005), non-diabetic (P=.005), had higher serum albumin (P=.028), lower alpha-fetoprotein level (P=.026), lower aspartate aminotransferase (AST) (P=.04) levels, and were treatment-naïve (P=.008). In a multivariate regression analysis, the independent predictors of SVR were younger age (P=.016), lower serum AST (P=.012), and being treatment naïve (P=.021). Conclusion: Approximately half of HCV-4 patients who complete the course of combination therapy achieve an SVR, especially if they are young, treatment naïve and have lower AST levels.

AB - Background and objectives: Knowledge of the predictors of sustained viral response (SVR) to pegylated interferon (PEG-INF) alfa-2a and ribavirin (RBV) therapy in patients with hepatitis C genotype-4 (HCV-4) is crucial for selecting patients who would benefit most from therapy. We assessed the predictors of SVR to this combination therapy in Saudi patients with chronic HCV-4 infection. Patients and methods: This retrospective study included 148 patients with HCV-4 infection who underwent clinical, biochemical and virological assessments before treatment and at 12, 24, 48 and 72 weeks post-treatment. Results: Of the 148 patients, 90 (60.8%) were males. Mean (SD) for age was 48. 5 (12.7) years and BMI was 27.9 (7.5) kg/m2. Seventy-nine of 148 (60.1%) patients were treatment naïve and 110 (74.3%) underwent pre-treatment liver biopsy. Eighteen (12.2%) patients did not complete therapy because of side effects or they were lost to follow up. Early virological response was achieved in 84 of 91 (92.3%) patients. In the 130 (87.8%) patients who completed therapy, 34 (26.2%) were non-responders and 96 (63.8%) achieved end-of-treatment virological response (ETVR). SVR and virological relapse (24 weeks after ETVR) occurred in 66/130 (50.7%) and 30/130 (31.2%) patients, respectively. Compared to relapsers, sustained responders were significantly younger (P=.005), non-diabetic (P=.005), had higher serum albumin (P=.028), lower alpha-fetoprotein level (P=.026), lower aspartate aminotransferase (AST) (P=.04) levels, and were treatment-naïve (P=.008). In a multivariate regression analysis, the independent predictors of SVR were younger age (P=.016), lower serum AST (P=.012), and being treatment naïve (P=.021). Conclusion: Approximately half of HCV-4 patients who complete the course of combination therapy achieve an SVR, especially if they are young, treatment naïve and have lower AST levels.

UR - http://www.scopus.com/inward/record.url?scp=60149090711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60149090711&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 4

EP - 14

JO - Annals of Saudi Medicine

JF - Annals of Saudi Medicine

SN - 0256-4947

IS - 1

ER -